{"version":"1.0","provider_name":"\u541b\u5b9e\u751f\u7269","provider_url":"https:\/\/www.junshipharma.com\/en\/","title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"A4lysMV8GJ\"><a href=\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\">Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/embed\/#?secret=A4lysMV8GJ\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint&#8221; &#8212; \u541b\u5b9e\u751f\u7269\" data-secret=\"A4lysMV8GJ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","thumbnail_width":2297,"thumbnail_height":1531,"description":"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future."}